COVID-19 Trial of the Candidate Vaccine MVA-SARS-2-S in Adults
Covid19
About this trial
This is an interventional prevention trial for Covid19 focused on measuring MVA, vaccine, SARS-CoV-2
Eligibility Criteria
Inclusion Criteria: Written informed consent. Male and female adults in stable health conditions aged 18 - 64 at time of informed consent (participation of health care workers and risk groups will be prioritized) and male or female in stable health conditions aged ≥ 65 at time of informed consent. Either in good or stable health in the opinion of the investigator. Participants may have underlying illness as long as their symptoms are medically controlled, and they are on a stable medication for the respective underlying illness for at least 8 weeks before screening and no changes are expected during the study. Body mass index 18.5 - 32.0 kg/m2 and weight > 50 kg at screening. Non-pregnant, non-lactating female with negative pregnancy test. Females who agree to comply with the applicable contraceptive requirements of the protocol. Exclusion Criteria: Receipt of any vaccine from 4 weeks prior to each trial vaccination (8 weeks for live vaccines) to 6 weeks after each trial vaccination. Previous rMVA immunization. Evidence of an active SARS-CoV-2 infection. Known allergy to the components of the MVA-SARS-2-S vaccine product such as chicken proteins, or history of life-threatening reactions to vaccine containing the same substances. Known history of anaphylaxis to vaccination or any allergy likely to be exacerbated by any component of the trial vaccine. Evidence in the participant's medical history or in the medical examination that might influence either the safety of the participant or the absorption, distribution, metabolism or excretion of the investigational product under investigation. Clinically relevant findings in ECG or significant thromboembolic events in medical history. Any confirmed or suspected immunosuppressive or immunodeficient condition, cytotoxic therapy in the previous 5 years, and/or uncontrolled diabetes (HbA1c > 7.0). Any known chronic or active neurologic disorder, including seizures, and epilepsy, excluding a single febrile seizure as a child.
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm 3
Experimental
Experimental
Placebo Comparator
1x10E7 IU (low dose)
1x10E8 IU (high dose)
Placebo
1x10E7 IU MVA-SARS-2-S Intervention: Biological: MVA-SARS-2-S vaccinations (days 0 & 28)
1x10E8 MVA-SARS-2-S Intervention: Biological: MVA-SARS-2-S vaccinations (days 0 & 28)
Days 0 & 28